Specific miRNAs Change After 3 Months of GH treatment and Contribute to Explain the Growth Response After 12 Months.
GH deficiency
GH treatment
growth
miR-199a-5p
miR-335-5p
miR-494-3p
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
03
2022
accepted:
21
04
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
There is growing evidence of the role of epigenetic regulation of growth, and miRNAs potentially play a role. The aim of this study is to identify changes in circulating miRNAs following GH treatment in subjects with isolated idiopathic GH deficiency (IIGHD) after the first 3 months of treatment, and verify whether these early changes can predict growth response. The expression profiles of 384 miRNAs were analyzed in serum in 10 prepubertal patients with IIGHD (5 M, 5 F) at two time points before starting GH treatment (t-3, t0), and at 3 months on treatment (t+3). MiRNAs with a fold change (FC) >+1.5 or <-1.5 at t+3 were considered as differentially expressed. Sixteen miRNAs were upregulated and 2 were downregulated at t+3 months. MiR-199a-5p ( MiR-199a-5p, miR-335-5p, and miR-494-3p changed after 3 months of GH treatment and likely reflected both the degree of GH deficiency and the sensitivity to treatment. Furthermore, they were of considerable importance to predict growth response.
Identifiants
pubmed: 35813630
doi: 10.3389/fendo.2022.896640
pmc: PMC9256936
doi:
Substances chimiques
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
896640Informations de copyright
Copyright © 2022 Catellani, Ravegnini, Sartori, Righi, Lazzeroni, Bonvicini, Poluzzi, Cirillo, Predieri, Iughetti, Giorgi Rossi, Angelini and Street.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Drug Test Anal. 2014 Mar;6(3):234-8
pubmed: 23495241
Aging Cell. 2014 Aug;13(4):679-89
pubmed: 24803090
Horm Res Paediatr. 2020;93(1):7-15
pubmed: 31914447
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17016-21
pubmed: 17942673
Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1092-103
pubmed: 25961547
Int J Environ Res Public Health. 2019 Feb 13;16(4):
pubmed: 30781749
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Clin Obes. 2017 Aug;7(4):216-221
pubmed: 28397375
J Anim Sci Biotechnol. 2012 Feb 28;3(1):4
pubmed: 22958414
J Cell Sci. 2009 Mar 1;122(Pt 5):716-26
pubmed: 19208758
Nat Med. 2008 Jul;14(7):723-30
pubmed: 18587408
J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3
pubmed: 11095419
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
J Endocrinol Invest. 2016 Jun;39(6):667-77
pubmed: 27223400
Cancer Biol Ther. 2015;16(7):1056-70
pubmed: 25962089
BMC Dev Biol. 2008 Apr 11;8:40
pubmed: 18405384
Sci Rep. 2018 Jul 11;8(1):10461
pubmed: 29992971
J Pediatr Endocrinol Metab. 2017 Oct 26;30(10):1019-1026
pubmed: 28902629
Eur J Endocrinol. 2001 Jan;144(1):13-20
pubmed: 11174832
J Endocrinol Invest. 2006 Sep;29(8):732-7
pubmed: 17033263
Arch Dis Child. 1966 Dec;41(220):613-35
pubmed: 5927918
Front Endocrinol (Lausanne). 2013 Jun 04;4:64
pubmed: 23761782
Int J Mol Sci. 2016 Oct 13;17(10):
pubmed: 27754357
J Clin Endocrinol Metab. 2003 Apr;88(4):1455-63
pubmed: 12679422
Eur J Endocrinol. 2016 May;174(5):681-91
pubmed: 26903552
Arch Dis Child. 1995 Jul;73(1):25-9
pubmed: 7639544
Front Genet. 2015 Jan 13;5:472
pubmed: 25628647
Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251
pubmed: 32484539
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Nat Rev Genet. 2008 Feb;9(2):102-14
pubmed: 18197166
Endocr Regul. 2006 Jun;40(2):37-45
pubmed: 17100545
Aging Cell. 2021 Jul;20(7):e13420
pubmed: 34118183
J Bone Miner Res. 2011 Aug;26(8):1953-63
pubmed: 21351149
Cytokine Growth Factor Rev. 2018 Feb;39:1-18
pubmed: 29398400
J Clin Res Pediatr Endocrinol. 2019 Jul 09;11(4):329-340
pubmed: 31284701
Endocr J. 2013;60(10):1131-44
pubmed: 23823978
Exp Clin Endocrinol Diabetes. 2015 Apr;123(4):209-14
pubmed: 25607339
J Bone Miner Res. 2017 Dec;32(12):2466-2475
pubmed: 28846804
Mol Endocrinol. 2014 Sep;28(9):1448-59
pubmed: 25073105
Gene. 2020 Feb 5;726:144193
pubmed: 31669647
J Bone Miner Res. 2014 Jul;29(7):1575-85
pubmed: 24347469